BMS, Tsinghua University to develop therapies for autoimmune diseases, cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Bristol-Myers Squibb Co. and Tsinghua University have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers.

The collaboration brings together BMS and Tsinghua University’s scientific expertise and capabilities with a focus on validating new targets and generating early drug candidates for clinical development.

Under the collaboration, The Innovation Center for Immune Therapy of Tsinghua University will conduct research on projects and BMS will have an option to exclusively license therapeutic agents discovered by Tsinghua University.

The collaboration is an expansion of an existing relationship between Bristol-Myers Squibb and Tsinghua University that began in 2012, which focused on autoimmune target discovery, structural biology research, as well as the science of mapping the 3D protein structure of biological molecular targets.

YOU MAY BE INTERESTED IN

When Judith O. Hopkins started medical school in 1974, she had to sign a contract promising to not get pregnant.  This was not the most egregious form of sexism she would face in her career. Seeking a residency in emergency medicine in 1977, she was told point blank that she would not be considered. “I...

Login